SCHEMBL755583

SCHEMBL755583

C[C@@H](c1ccc(-c2ccc(C(=O)O)c(F)c2)cc1Cl)[C@](O)(c1ccc(=O)n(C)c1)C(F)(F)F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.34
DPP7 Q9UHL4 5/20 0.34
RARB P10826 3/20 0.33
RARA P10276 2/20 0.33
RARG P13631 1/20 0.33
F9 P00740 1/20 0.32
AKR1C2 P52895 1/20 0.32
AKR1C1 Q04828 1/20 0.32
F11 P03951 1/20 0.32
KLKB1 P03952 1/20 0.32
RORC P51449 1/20 0.32
PPARG P37231 1/20 0.31
RXRA P19793 1/20 0.31
RXRB P28702 1/20 0.31
PDE2A O00408 1/20 0.31
MAP2K2 P36507 1/20 0.31
MAP2K1 Q02750 1/20 0.31
PDK2 Q15119 1/20 0.31
FFAR1 O14842 1/20 0.31
MET P08581 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL732428 1.00 DPP4 (0.34) DPP4DPP7RARBRARARARG
SCHEMBL734223 0.93 PDK2 (0.36) DPP4DPP7F9AKR1C2AKR1C1
SCHEMBL755587 0.93 PDK2 (0.36) DPP4DPP7F9AKR1C2AKR1C1
SCHEMBL754902 0.93 DPP4 (0.34) DPP4DPP7F9AKR1C2AKR1C1
SCHEMBL480062 0.93 DPP4 (0.34) DPP4DPP7F9AKR1C2AKR1C1
SCHEMBL732991 0.91 GRIK1 (0.35) DPP4DPP7AKR1C2AKR1C1PDE2A
SCHEMBL753053 0.91 GRIK1 (0.35) DPP4DPP7AKR1C2AKR1C1PDE2A
SCHEMBL752282 0.90 KDM4E (0.36) DPP4DPP7F9RORCPDK2
SCHEMBL732326 0.90 KDM4E (0.36) DPP4DPP7F9RORCPDK2
SCHEMBL753303 0.89 RARB (0.36) DPP4DPP7RARBRARARARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 DPP4 727/4885DPP7 1548/4885RARB 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.